While 2023 may have been the year of AI for the consumer consciousness, for companies using the technology in a focused way in drug development it was just another year of learning and adva
Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.
